Frank Borriello

Frank Borriello, MD, PhD

Scientific Founder & Chief Executive Officer

Frank Borriello, MD, PhD leads Alloplex Biotherapeutics Inc., a private Boston-based company he founded in 2016 based on an original and now patented concept, as Chief Executive Officer.

Dr. Borriello obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he studied Class I MHC structure-function relationships. He continued training at the Brigham and Women’s Hospital in Boston with a residency in clinical pathology and a laboratory research focus in cellular immunology and the B7-CD28 costimulatory pathway.

He has an extensive 20+ year background in the biotech/pharma industry spanning diverse roles such as clinical development (Wyeth), financial buy-side analyst (BB Biotech) and, most extensively, in the area of Business Development (Millennium, Takeda, Shire and Baxter) and, finally Baxalta, where he was VP of Search and Evaluation before its acquisition in 2016.

In 2016, he conceived a potentially differentiated, non-engineered approach to immuno-oncology (now ‘SUPLEXA’) and established Alloplex Biotherapeutics Inc.

Since then – as Scientific Founder and CEO of Alloplex – Dr. Borriello has led the organization through research, fundraising and business development, to Phase 1 clinical trials for SUPLEXA therapy which commenced recently in Australia.

SUPLEXA is a potential first-in-class, autologous, pan cancer-cellular therapy made from the patient’s own immune cells, and comprised primarily of cells with known anti-tumor killing cells such as NK cells, NKT cells and T cells.

Selected Publications

Descending date order

  • OX-2 defines a novel T cell costimulatory pathway.

    Journal of Immunology 1997: 158[6] : 4548-4554.

    Borriello F, Lederer J, Scott S and AH Sharpe.
  • B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center Formation.

    Immunity 1997: 6: 303-313.

    Borriello F, Sethna SP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ and AH Sharpe.
  • Differential expression of alternate mB7-2 transcripts.

    Immunol. 1995 Dec 15;155(12):5490-7.

    Borriello F, Oliveros J, Freeman GJ, Nadler LM, Sharpe AH.
  • Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4.

    Immunity 1995: 3: 541-547

    Tivol B, Borriello F, Schweitzer NA, Lynch WP, Bluestone JA and AH Sharpe.
  • Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation.

    Immunol. 1995 Jan;25(1):207-11.

    Prabhu Das MR, Zamvil SS, Borriello F, Weiner HL, Sharpe AH, Kuchroo VK.
  • Uncovering of Functional Alternative CTLA-4 Counter-receptor in B7-Deficient Mice.

    Prabhu Das MR, Zamvil SS, Borriello F, Weiner HL, Sharpe AH, Kuchroo VK.

    Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM and AH Sharpe.
  • Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production.

    Journal of Experimental Medicine 1993: 178: 2185-2188.

    Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg J, Hathcock K, Laszlo G, Lombard L, Wang S, Gray GS, Nadler LM and AH Sharpe.
  • Multiple murine alpha 1-protease inhibitor genes show unusual evolutionary divergence.

    Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9417-21.

    Borriello F, Krauter KS.
  • Reactive site polymorphism in the murine protease inhibitor gene family is delineated using a modification of the PCR reaction (PCR + 1).

    Nucleic Acids Res. 1990 Sep 25;18(18):5481-7.

    Borriello F, Krauter KS.
  • Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia.

    Blood. 1991 Jul 15;78(2):524-32

    Zeff RA, Zhao YF, Tatake R, Lachman H, Borriello F, Nathenson SG.
  • Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor.

    Cell. 1988 Jul 1;54(1):47-56.

    Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG.
  • Intracellular transport of class I histocompatibility molecules. Influence of protein folding on transport to the cell surface.

    Biol Chem. 1988 Apr 5;263(10):4549-60.

    Williams DB, Borriello F, Zeff RA, Nathenson SG
  • Somatic cell variants of the murine major histocompatibility complex.

    Immunol Res. 1987;6(1-2):133-44.

    Zeff RA, Kumar PA, Mashimo H, Nakagawa M, McCue B, Borriello F, Kesari K, Geliebter J, Hemmi S, Pfaffenbach G, et al.